Rate of clinical progression in Parkinson's disease. A prospective study

被引:126
|
作者
Schrag, Anette [1 ]
Dodel, Richard
Spottke, Annika
Bornschein, Bernhard
Siebert, Uwe
Quinn, Niall P.
机构
[1] UCL, Dept Clin Neurosci, Royal Free Hosp, London NW3 2PF, England
[2] UCL, Dept Motor Neurosci & Movement Disorders, Inst Neurol, London, England
[3] Univ Marburg, Dept Neurol, Marburg, Germany
[4] UMIT Univ Hlth Sci Med Informat & Technol, Hall, Germany
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
Parkinson's disease; progression; UPDRS; scales;
D O I
10.1002/mds.21429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic-based sample of 145 patients over 1 year and in a community-based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow-up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow-up in the community-based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic-based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. (C) 2007 Movement Disorder Society.
引用
收藏
页码:938 / 945
页数:8
相关论文
共 50 条
  • [1] Levodopa and the progression of Parkinson's disease.
    Morgan J.
    Sethi K.D.
    [J]. Current Neurology and Neuroscience Reports, 2005, 5 (4) : 261 - 262
  • [2] Prospective study of education, occupation, and risk of Parkinson's disease.
    Weisskopf, M. G.
    O'Reilly, E.
    McCullough, M. L.
    Calle, E. E.
    Thun, M. J.
    Schwarzschild, M. A.
    Ascherio, A.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : S178 - S178
  • [3] Cigarette smoking in Parkinson's disease. Influence on disease progression
    Alves, G
    Kurz, M
    Aarsland, D
    Larsen, JP
    [J]. MOVEMENT DISORDERS, 2002, 17 : S154 - S154
  • [4] The clinical progression of Parkinson's disease
    Poewe, Werner
    Mahlknecht, Philipp
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 : S28 - S32
  • [5] Progression in Parkinson's disease. An 18F-FDOPA PET study
    Juri, C.
    Aibizu, J.
    Rodriguez-Oroz, M.
    Prieto, E.
    Marti, J. M.
    Richter, J.
    Obeso, J.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S60 - S60
  • [6] Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation
    Phylinda L. S. Chan
    John G. Nutt
    Nicholas H. G. Holford
    [J]. Pharmaceutical Research, 2007, 24 : 791 - 802
  • [7] Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation
    Chan, Phylinda L. S.
    Nutt, John G.
    Holford, Nicholas H. G.
    [J]. PHARMACEUTICAL RESEARCH, 2007, 24 (04) : 791 - 802
  • [8] Handedness and the rate of Parkinson's disease progression
    Trufanov, Y. O.
    [J]. MOVEMENT DISORDERS, 2013, 28 : S161 - S162
  • [9] A Prospective Study for Biomarker Identification in Early Parkinson Disease.
    Tanner, C.
    [J]. MOVEMENT DISORDERS, 2012, 27 (04) : E7 - E8
  • [10] Clinical diagnosis of Parkinson's disease. When to order a neuroimaging study?
    Jose Catalan-Alonso, Maria
    [J]. REVISTA DE NEUROLOGIA, 2010, 50 : S14 - S15